Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel therapies that target the complement system for the prevention and treatment of rare diseases, organ transplant rejection and certain inflammatory conditions. Its lead product candidate, nomacopan, is an investigational, small‐protein dual inhibitor of complement component C5 and leukotriene B4, designed to address the underlying drivers of tissue damage in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), bullous pemphigoid and cutaneous acute graft-versus-host disease. In addition to nomacopan, Jasper’s pipeline includes earlier-stage complement inhibitors aimed at improving transplant outcomes in kidney and other solid-organ recipients.

Founded in 2015 as a spin-out from the University of Pennsylvania and the University of Washington, Jasper Therapeutics completed its initial public offering on the Nasdaq in 2018. The company has established strategic collaborations and license agreements to support global development and commercialization, leveraging partnerships with leading pharmaceutical firms to expand the reach of its complement‐modulating technology. Headquartered in Plymouth, Minnesota, Jasper conducts multi‐center clinical trials across North America, Europe and Australia.

Jasper’s management team brings deep expertise in immunology, rare disease development and regulatory strategy. The company is led by a seasoned executive team and board of directors with decades of experience guiding small and mid‐sized biopharmaceutical enterprises through late‐stage clinical trials and toward potential commercialization. This leadership collective underscores Jasper’s commitment to advancing its pipeline and delivering transformative therapies for patients with high‐unmet medical needs.

Key Stats

• Today's Range: $3.41 to $3.84
• 50-Day Range: $3.02 to $7.04
• 52-Week Range: $2.27 to $26.05
• Volume: 845,360 shs
• Average Volume: 397,367 shs
• Market Capitalization: $53.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.75
• Consensus Rating: Moderate Buy

Jasper Therapeutics Stock Analysis - MarketRank™

Jasper Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 315th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jasper Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jasper Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($4.47) to ($4.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jasper Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jasper Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jasper Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.23% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jasper Therapeutics does not currently pay a dividend.

Dividend Growth

Jasper Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.23% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: -0.33

News Sentiment

Jasper Therapeutics has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Jasper Therapeutics this week, compared to 3 articles on an average week.

Search Interest

16 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

19 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 46% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Jasper Therapeutics is held by insiders.

Percentage Held by Institutions

79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JSPR Stock Analysis - Frequently Asked Questions

How have JSPR shares performed this year?

Jasper Therapeutics' stock was trading at $21.38 at the beginning of the year. Since then, JSPR stock has decreased by 83.4% and is now trading at $3.55.

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) issued its quarterly earnings data on Monday, May, 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $0.24.

When did Jasper Therapeutics' stock split?

Jasper Therapeutics shares reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jasper Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JSPR
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jasper Therapeutics: $29.75
• High Price Target: $65.00
• Low Price Target: $5.00
• Potential Upside/Downside: +738.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -109.45%
• Return on Assets: -89.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.31
• Quick Ratio: 4.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.11 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 15,020,000
• Free Float: 14,331,000
• Market Cap: $53.32 million
• Optionable: Optionable
• Beta: 2.69